These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 18793808

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE.
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [Abstract] [Full Text] [Related]

  • 3. Cystatin C and creatinine as markers for radiocontrast-induced nephropathy in patients treated with N-acetylcysteine.
    Merkle M, Sauter M, Argirov M, Wörnle M.
    Ren Fail; 2010 Jan; 32(1):85-90. PubMed ID: 20113272
    [Abstract] [Full Text] [Related]

  • 4. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention.
    Ochoa A, Pellizzon G, Addala S, Grines C, Isayenko Y, Boura J, Rempinski D, O'Neill W, Kahn J.
    J Interv Cardiol; 2004 Jun; 17(3):159-65. PubMed ID: 15209578
    [Abstract] [Full Text] [Related]

  • 5. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS.
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy.
    Kinbara T, Hayano T, Ohtani N, Furutani Y, Moritani K, Matsuzaki M.
    J Cardiol; 2010 Mar; 55(2):174-9. PubMed ID: 20206069
    [Abstract] [Full Text] [Related]

  • 8. [Prevention of contrast-induced nephropathy using cardiac catheterization combined with hydration, oral N-acetylcysteine, sodium bicarbonate and iso-osmolar contrast agents].
    Hoshino A, Enomoto S, Kawahito H, Kurata H, Nakahara Y, Nakamura T.
    J Cardiol; 2007 Aug; 50(2):119-26. PubMed ID: 17802695
    [Abstract] [Full Text] [Related]

  • 9. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F, Ozdemir K, Kaya MG, Dogdu O, Vatankulu MA, Ayhan S, Erkorkmaz U, Sonmez O, Aygul MU, Kalay N, Kayrak M, Karabag T, Alihanoglu Y, Gunebakmaz O.
    Int J Cardiol; 2012 Mar 22; 155(3):418-23. PubMed ID: 21106264
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prevention of contrast-induced nephropathy by N-acetylcysteine in critically ill patients: different definitions, different results.
    Chousterman BG, Bouadma L, Moutereau S, Loric S, Alvarez-Gonzalez A, Mekontso-Dessap A, Laissy JP, Rahmouni A, Katsahian S, Brochard L, Schortgen F.
    J Crit Care; 2013 Oct 22; 28(5):701-9. PubMed ID: 23683568
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
    Habib M, Hillis A, Hammad A.
    Saudi J Kidney Dis Transpl; 2016 Jan 22; 27(1):55-61. PubMed ID: 26787567
    [Abstract] [Full Text] [Related]

  • 14. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.
    Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G, Erbs S, Linke A, Diederich KW, Nowak M, Desch S, Gutberlet M, Schuler G.
    J Am Coll Cardiol; 2010 May 18; 55(20):2201-9. PubMed ID: 20466200
    [Abstract] [Full Text] [Related]

  • 15. Use of NaCl saline hydration and N-Acetyl Cysteine to prevent contrast induced nephropathy in different populations of patients at high and low risk undergoing coronary artery angiography.
    Calabrò P, Bianchi R, Caprile M, Sordelli C, Cappelli Bigazzi M, Palmieri R, Gigantino G, Limongelli G, Capozzi G, Cuomo S, Calabrò R.
    Minerva Cardioangiol; 2010 Feb 18; 58(1):35-40. PubMed ID: 20145594
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography.
    Acikel S, Muderrisoglu H, Yildirir A, Aydinalp A, Sade E, Bayraktar N, Bal U, Ozin B.
    Blood Coagul Fibrinolysis; 2010 Dec 18; 21(8):750-7. PubMed ID: 20962623
    [Abstract] [Full Text] [Related]

  • 20. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide.
    Morikawa S, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, Morita Y, Numaguchi Y, Okumura K, Murohara T.
    J Am Coll Cardiol; 2009 Mar 24; 53(12):1040-6. PubMed ID: 19298916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.